BR112014014378A2 - composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico - Google Patents

composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico Download PDF

Info

Publication number
BR112014014378A2
BR112014014378A2 BR112014014378A BR112014014378A BR112014014378A2 BR 112014014378 A2 BR112014014378 A2 BR 112014014378A2 BR 112014014378 A BR112014014378 A BR 112014014378A BR 112014014378 A BR112014014378 A BR 112014014378A BR 112014014378 A2 BR112014014378 A2 BR 112014014378A2
Authority
BR
Brazil
Prior art keywords
composition
nucleic acid
eye disease
disease related
treat eye
Prior art date
Application number
BR112014014378A
Other languages
English (en)
Inventor
Jain Sandeep
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BR112014014378A2 publication Critical patent/BR112014014378A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eyeglasses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo “composição e método para tratar doença ocular relacionada a ácido nucleico” proporcionada aqui é uma composição e um método para tratar doença ocular relacionada a ácido nucleico.
BR112014014378A 2011-12-12 2012-08-20 composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico BR112014014378A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569604P 2011-12-12 2011-12-12
US201261600377P 2012-02-17 2012-02-17
PCT/US2012/051562 WO2013089835A1 (en) 2011-12-12 2012-08-20 Composition and method for treating nucleic acid-related eye disease

Publications (1)

Publication Number Publication Date
BR112014014378A2 true BR112014014378A2 (pt) 2020-05-19

Family

ID=48613071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014378A BR112014014378A2 (pt) 2011-12-12 2012-08-20 composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico

Country Status (15)

Country Link
US (3) US9867871B2 (pt)
EP (1) EP2790722B1 (pt)
JP (1) JP6202400B2 (pt)
KR (1) KR101898438B1 (pt)
CN (1) CN104220087A (pt)
AU (1) AU2012352983B2 (pt)
BR (1) BR112014014378A2 (pt)
CA (1) CA2858983C (pt)
DK (1) DK2790722T3 (pt)
ES (1) ES2713519T3 (pt)
IL (1) IL232999B (pt)
MX (1) MX364495B (pt)
RU (1) RU2642609C2 (pt)
WO (1) WO2013089835A1 (pt)
ZA (1) ZA201404320B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130297023A1 (en) * 2012-05-07 2013-11-07 Hee-Jeong Im Sampen Methods and Devices For Treating Intervertebral Disc Disease
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
RU2739392C2 (ru) * 2015-06-15 2020-12-23 Ордженезис Инк. Фармацевтические препараты для лечения вирусных инфекций глаза
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
EP3644966A4 (en) * 2017-06-29 2021-03-24 Advaite LLC TREATMENT AND DIAGNOSIS OF EYE SURFACE DISORDERS
EP3668972A4 (en) 2017-08-18 2021-04-21 Neutrolis Inc. CONSTRUCTED DNASE ENZYMS AND THEIR USES IN THERAPY
WO2019065936A1 (ja) * 2017-09-29 2019-04-04 参天製薬株式会社 涙液中のｍｕｃ５ａｃ量の測定方法
US11464672B2 (en) 2018-06-01 2022-10-11 Aurora Tears Technology, Inc. Systems and methods for generating and applying biomimicry tear films
US11253395B2 (en) * 2018-06-01 2022-02-22 Aurora Tears Technology, Inc. Systems and methods for generating and applying biomimicry tear films
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
SG11202103426XA (en) 2018-10-08 2021-05-28 Neutrolis Inc Engineering of dnase enzymes for manufacturing and therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
RU2740363C1 (ru) * 2020-08-03 2021-01-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оценки эффективности лечения синдрома сухого глаза у больных сахарным диабетом
BE1028712B1 (fr) * 2020-10-16 2022-05-18 Onelife S A Composition para-pharmaceutique ou pharmaceutique administrable à un être vivant, de préférence un être humain comprenant au moins une enzyme pour le traitement et/ou la prévention d'infections bactériennes impliquant la formation de biofilm
CN115595315A (zh) * 2021-06-28 2023-01-13 四川大学华西医院（Cn） 核糖核酸酶i在抑制疼痛的药物中的新用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1575359A1 (ru) 1988-06-14 1991-05-15 Институт Морфологии Человека Амн Ссср Способ получени рибонуклеотидов
US6241409B1 (en) 1997-07-29 2001-06-05 Andrew Holloway Pencils containing reclaimed rubber
GB9716376D0 (en) * 1997-08-01 1997-10-08 Isis Innovation Artificial tear formulation
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
US20080096817A1 (en) 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
US20040131626A1 (en) 2001-03-15 2004-07-08 Goldstein Allan L. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivatives
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050089546A1 (en) * 2003-09-16 2005-04-28 Dick Wurtman Compositions and methods comprising complex carbohydrate and alpha-lactalbumin
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20080139545A1 (en) * 2006-05-22 2008-06-12 Won-Taek Choe Formulation to treat ear infection
AU2008216147A1 (en) * 2007-02-15 2008-08-21 National Jewish Health Methods and compositions for the disruption of biofilms
WO2009002790A2 (en) * 2007-06-26 2008-12-31 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
ES2493641T3 (es) 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
GB2477914B (en) * 2010-02-12 2012-01-04 Univ Newcastle Compounds and methods for biofilm disruption and prevention

Also Published As

Publication number Publication date
JP2015506920A (ja) 2015-03-05
DK2790722T3 (en) 2019-03-25
AU2012352983B2 (en) 2017-09-21
MX364495B (es) 2019-04-29
US9867871B2 (en) 2018-01-16
EP2790722A1 (en) 2014-10-22
AU2012352983A1 (en) 2014-07-03
ZA201404320B (en) 2015-11-25
IL232999B (en) 2019-03-31
JP6202400B2 (ja) 2017-09-27
ES2713519T3 (es) 2019-05-22
CA2858983C (en) 2020-06-09
US11376312B2 (en) 2022-07-05
RU2642609C2 (ru) 2018-01-25
CN104220087A (zh) 2014-12-17
CA2858983A1 (en) 2013-06-20
MX2014007103A (es) 2015-05-11
KR101898438B1 (ko) 2018-09-14
US20150010524A1 (en) 2015-01-08
WO2013089835A1 (en) 2013-06-20
EP2790722A4 (en) 2015-09-09
US10328129B2 (en) 2019-06-25
US20170106057A1 (en) 2017-04-20
US20190314461A1 (en) 2019-10-17
IL232999A0 (en) 2014-07-31
EP2790722B1 (en) 2018-12-05
KR20140101857A (ko) 2014-08-20
RU2014128564A (ru) 2016-02-10

Similar Documents

Publication Publication Date Title
BR112014014378A2 (pt) composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico
BR112015010360A8 (pt) antagonistas de il-6 e utilização dos mesmos.
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014010186A2 (pt) formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
EA201201648A1 (ru) Стимуляторы sgc
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112013025386A2 (pt) combinação de um composto, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de uma doença ou afecção modulada por mutação braf v600e e altos níveis de pakt em um mamífero e uso
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
BR112013009142A2 (pt) "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa"
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
BR112014005389A8 (pt) Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
HRP20130830T1 (en) A water-in-oil type emulsion for treating a disease of the eye
BR112013024169A2 (pt) método para o tratamento e prevenção da doença de parkinson
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
CO6970598A2 (es) Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares
BR112015006512A2 (pt) composição para tratar tecidos biológicos danificados
HK1186660A1 (en) A water-in-oil type emulsion for treating a disease of the eye
BR112013025397A2 (pt) combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]